Subject Category | Â | Â | LDX Optimal Dose | Â | Â |
---|---|---|---|---|---|
 |  | 30 mg/d | 50 mg/d | 70 mg/d | All Doses |
Safety population | Â | 58 (100.0) | 50 (100.0) | 21 (100.0) | 129 (100.0) |
Age (years) | Mean (SD) | 9.8 (1.5) | 10.2 (1.3) | 10.4 (1.9) | 10.1 (1.5) |
Gender | Â | Â | Â | Â | Â |
Male | n (%) | 44 (75.9) | 37 (74.0) | 17 (81.0) | 98 (76.0) |
Female | Â | 14 (24.1) | 13 (26.0) | 4 (19.0) | 31 (24.0) |
Race | Â | Â | Â | Â | Â |
Caucasian | Â | 38 (65.5) | 37 (74.0) | 16 (76.2) | 91 (70.5) |
Black or African American | Â | 11 (19.0) | 4 (8.0) | 2 (9.5) | 17 (13.2) |
Native Hawaiian or Other Pacific Islander | n (%) | 0 | 1 (2.0) | 0 | 1 (0.8) |
Asian | Â | 0 | 0 | 0 | 0 |
American Indian or Alaska Native | Â | 2 (3.4) | 0 | 0 | 2 (1.6) |
Other | Â | 7 (12.1) | 8 (16.0) | 3 (14.3) | 18 (14.0) |
Ethnicity | Â | Â | Â | Â | Â |
Hispanic or Latino | n (%) | 9 (15.5) | 11 (22.0) | 6 (28.6) | 26 (20.2) |
Not Hispanic or Latino | Â | 49 (84.5) | 39 (78.0) | 15 (71.4) | 103 (79.8) |
ADHD-RS-IV Total Score at Baseline | Mean (SD) | 40.5 (6.7) | 43.4 (7.5) | 45.7 (5.7) | 42.4 (7.1) |
Randomized population | Â | 46 (79.3) | 50 (100.0) | 21 (100.0) | 117 (90.7) |
Intent-to-treat population | Â | 46 (79.3) | 47 (94.0) | 20 (95.2) | 113 (87.6) |
Completed study | Â | 44 (75.9) | 47 (94.0) | 20 (95.2) | 111 (86.0) |
Reason for discontinuation* | Â | Â | Â | Â | Â |
Adverse event†|  | 8 (13.8) | 1 (2.0) | 0 | 9 (7.0) |
Protocol violation | Â | 1 (1.7) | 1 (2.0) | 0 | 2 (1.6) |
Consent withdrawn | Â | 3 (5.2) | 1 (2.0) | 1 (4.8) | 5 (3.9) |
Lost to follow-up | Â | 2 (3.4) | 0 | 0 | 2 (1.6) |
Lack of efficacy | Â | 0 | 0 | 0 | 0 |
Other | Â | 0 | 0 | 0 | 0 |